197 related articles for article (PubMed ID: 30056080)
1. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080
[TBL] [Abstract][Full Text] [Related]
2. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer.
Gomez CL; Xu X; Qi XS; Wang PC; Kupelian P; Steinberg M; King CR
Pract Radiat Oncol; 2015; 5(4):257-62. PubMed ID: 25749214
[TBL] [Abstract][Full Text] [Related]
4. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.
Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE
Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457
[TBL] [Abstract][Full Text] [Related]
5. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
Dess RT; Jackson WC; Suy S; Soni PD; Lee JY; Abugharib AE; Zumsteg ZS; Feng FY; Hamstra DA; Collins SP; Spratt DE
Cancer; 2017 May; 123(9):1635-1642. PubMed ID: 28001303
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
7. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.
Elias E; Helou J; Zhang L; Cheung P; Deabreu A; D'Alimonte L; Sethukavalan P; Mamedov A; Cardoso M; Loblaw A
Radiother Oncol; 2014 Jul; 112(1):83-8. PubMed ID: 25005578
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
King CR; Collins S; Fuller D; Wang PC; Kupelian P; Steinberg M; Katz A
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):939-45. PubMed ID: 24119836
[TBL] [Abstract][Full Text] [Related]
10. Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer.
Magli A; Farneti A; Faiella A; Ferriero M; Landoni V; Giannarelli D; Moretti E; de Paula U; Gomellini S; Sanguineti G
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):93-100. PubMed ID: 33745951
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial.
Wages NA; Sanders JC; Smith A; Wood S; Anscher MS; Varhegyi N; Krupski TL; Harris TJ; Showalter TN
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1254-1262. PubMed ID: 33227441
[TBL] [Abstract][Full Text] [Related]
12. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Repka MC; Carrasquilla M; Paydar I; Wu B; Lei S; Suy S; Collins SP; Kole TP
Acta Oncol; 2023 Feb; 62(2):174-179. PubMed ID: 36826994
[TBL] [Abstract][Full Text] [Related]
14. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.
Hanlon AL; Watkins Bruner D; Peter R; Hanks GE
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497
[TBL] [Abstract][Full Text] [Related]
15. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
Quon HC; Ong A; Cheung P; Chu W; Chung HT; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A
Radiother Oncol; 2018 May; 127(2):206-212. PubMed ID: 29551231
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer.
Parikh NR; Kishan AU; Kane N; Diaz-Perez S; Ganapathy E; Nazarian R; Felix C; Mathis C; Bradley M; Sachdeva A; Wyatt B; Basehart V; Zomorodian N; Lin L; King CR; Kupelian PA; Rettig MB; Steinberg ML; Cao M; Knudsen BS; Elashoff D; Schaue D; Reiter RE; Nickols NG
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):930-935. PubMed ID: 32562839
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning.
Pan X; Levin-Epstein R; Huang J; Ruan D; King CR; Kishan AU; Steinberg ML; Qi XS
Radiother Oncol; 2020 Jul; 148():181-188. PubMed ID: 32388444
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.
Ballas LK; Luo C; Chung E; Kishan AU; Shuryak I; Quinn DI; Dorff T; Jhimlee S; Chiu R; Abreu A; Jennelle R; Aron M; Groshen S
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):50-60. PubMed ID: 30605751
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
[TBL] [Abstract][Full Text] [Related]
20. Proctitis following stereotactic body radiation therapy for prostate cancer.
Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]